GMAB

Investor Moves

Name	Value	Action	Change	Price	Current Price
Ken GriffinCitadel Advisors $5M172.5k shares AddQ1 2026 $3M $26.83 $29.17
Jim SimonsRenaissance Technologies $118M4.4M shares AddQ1 2026 $11M $26.83 $29.17
Ken GriffinCitadel Advisors $-988.2K TrimQ4 2025 $988k -- $29.17
Jim SimonsRenaissance Technologies $21.0M AddQ4 2025 $21M -- $29.17
Ken GriffinCitadel Advisors $-71.9M TrimQ3 2025 $72M -- $29.17
Steven CohenPoint72 $-11.1M ExitQ3 2025 $11M -- $29.17

Congress Trades

Name	Value	Action	Amount Range	Price	Current Price
Josh GottheimerDemocrat $8k BuyJan 16, 2025 $1k-$15k -- $29.17
Josh GottheimerDemocrat $8k OtherDec 16, 2024 $1k-$15k -- $29.17
Josh GottheimerDemocrat $8k BuyJul 19, 2024 $1k-$15k -- $29.17

News

globenewswire.comCapital Increase in Genmab as a Result of Employee Warrant Exerciseglobenewswire.comJun 16

globenewswire.comMajor Shareholder Announcementglobenewswire.comJun 15

gurufocus.comGenmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)gurufocus.comJun 13

globenewswire.comGenmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)globenewswire.comJun 13

businesswire.comGenmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)businesswire.comJun 13

Trade GMAB

About Genmab A/S

Genmab A/S, a biopharmaceutical company founded in 1999 and headquartered in Copenhagen, Denmark, specializes in the discovery and development of innovative antibody therapies primarily for treating cancer and various other serious illnesses. The company's commercialized portfolio includes several key products: DARZALEX (daratumumab), a human monoclonal antibody for multiple myeloma (MM), non-MM blood cancers, and AL amyloidosis; teprotumumab, indicated for thyroid eye disease; ofatumumab, another human monoclonal antibody used in chronic lymphocytic leukemia (CLL) and multiple sclerosis; Amivantamab, for advanced or metastatic gastric or esophageal cancer and non-small cell lung cancer (NSCLC); and tisotumab vedotin, which targets cervical, ovarian, and solid tumors. Genmab maintains a robust pipeline of investigational medicines. These include GEN1047; DuoBody-PD-L1x4-1BB and DuoBody-CD40x4-1BB, both developed for solid tumors; Epcoritamab, in development for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37, aimed at hematological malignancies. Furthermore, the company has several products in Phase 2 clinical trials: Teclistamab for vaso-occlusive crises; Camidanlumab tesirine for Hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 for MM; PRV-015 for celiac disease; Mim8 for haemophilia A; and Lu AF82422 for multiple system atrophy disease. In addition to its clinical programs, Genmab is advancing approximately 20 active pre-clinical programs. Genmab fosters strategic collaborations to further its research and development efforts. It holds a commercial license and co-development agreement with Seagen Inc. for tisotumab vedotin. The company also partners with CureVac AG on the research and development of differentiated mRNA-based antibody products and with AbbVie for the development of epcoritamab. Further alliances include BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc.

CEO: Jan van de Winkel
IPO Date: Jun 1, 2009

Market Data

Open: $25.68
High: $25.73
Low: $25.00
Volume: 1.8M
Avg Volume: 1.8M
52W High: $35.43
52W Low: $20.23

Valuation

Market Cap: $15.5B
Enterprise Value: $19.3B
Dividend Yield: 0.00%

Financials

Free Cash Flow: $1.1B
Revenue: $3.7B
Net Income: $963.8M
Cash: $1.7B
Debt: $5.4B

Events

EarningsAug 6

EPS est. 0.34